

CRISIL

Well Rated

CRISIL is the largest credit rating agency with a market share of around 65% and is one of the biggest research houses in India. With the recent acquisition of Pipal Research Corp. (Pipal), robust credit demand and strong infrastructure-spend, we expect strong growth across all the segments of the company. The company has also recently finished a buyback of 1.3lakh shares worth ₹80cr at an average price of ₹6,200. We Initiate Coverage on the stock with a Buy rating.

Acquisition of Pipal to boost research revenue: Pipal is a strong player providing offshore research services to the corporate sector, while CRISIL's Irevna is a leading offshore research provider to the financial sector. The synergy between the two firms will help CRISIL to service its clients better and further expand its client base, resulting in strong growth going ahead. Post the acquisition with the combined strength of the two firms we expect a 22% CAGR in the research segment's revenue over CY2010–12.

Robust growth in credit ratings to continue on strong credit demand: We believe credit demand will continue to grow at a faster rate than India's nominal GDP as financial depth continues to increase. The need for large capital formation of 30–35% of GDP for sustaining 8%+ GDP growth in India is well acknowledged; hence, we expect credit demand to witness 20% CAGR over CY2010–14, considering the actual and latent credit demand in India. CRISIL has been growing at \sim 2x India's credit growth since CY2005. Further, the company will continue to benefit from Basel-II norms, as a large number of entities are still to be rated. CRISIL, being the market leader with 65% market share in credit rating and 50% share in bank loan rating (BLR), will continue to benefit greatly from India's strong credit growth. We conservatively expect the segment to register 21% revenue CAGR over CY2010–12.

Outlook and valuation: We expect CRISIL to post 21.5% CAGR in revenues over CY2010–12 and continue to maintain its leadership position. CRISIL benefits from its asset-light business model, which is high on intellectual assets (employee cost-to-sales is around 40%). Further, the company is debt free and has 40% plus RoE. Additionally, CRISIL enjoys strong parentage (Standard and Poor's). Currently, the stock is available at 17.3x CY2012E earnings, which is at the lower end of its historical range of 16.4–29.9x one-year forward EPS. We Initiate Coverage on the stock with a Buy rating and a Target Price of ₹7,584, valuing it at its five-year median of 22x CY2012E earnings and implying an upside of 27%.

Key financials (Consolidated)

Y/E Dec. (₹ cr)	CY2009	CY2010E	CY2011E	CY2012E
Net sales	537	629	767	927
% chg	4.4	17.0	22.0	20.0
Adj. Net profit	161	157	200	245
% chg	14.4	(2.5)	27.7	22.3
FDEPS (₹)	223	284	282	345
EBITDA margin (%)	37.1	33.3	34.3	34.8
P/E (x)	26.9	21.0	21.2	17.3
RoE (%)	40.6	37.2	44.9	46.8
RoCE (%)	46.6	44.6	53.6	56.8
P/BV (x)	10.0	10.4	8.8	7.6
EV/Sales (x)	7.6	6.6	5.3	4.3
EV/EBITDA (x)	20.5	20.0	15.6	12.4
Source: Company, Angel Research		·		

BUY	
CMP	₹5,979
Target Price	₹7,584
Investment Period	12 Months
Sector	Credit R ating
Market Cap (₹ cr)	4,245
Beta	0.3
52 Week High /Low	6350/4290
Avg. Daily Volume	1,198
Face Value (₹)	10
BSE Sensex	19,224
Nifty	5,763
Reuters Code	CRSL.BO
Bloomberg Code	CR IS IL@IN

Shareholding Pattern (%)	
Promoters	52.4
MF /Banks /Indian Fls	19.4
FII /NR Is /OCBs	10.4
Indian Public / Others	17.8

Abs . (%)	3m	1yr	3yr
Sensex	(5.1)	9.6	(6.6)
CR IS IL	0.8	24.3	70.8

Sharan Lillaney

022- 3935 7800 Ext.: 6811

sharanb.lillaney@angelbroking.com



Investment arguments

CRISIL witnessed robust growth in the first three quarters of CY2010 on the back of strong credit growth and global economic recovery, which going ahead is expected to further improve. The company recently acquired Pipal Research, which will lend to a boost to their research portfolio and result in robust growth in the ensuing years. The advisory segment is expected to revert to high growth tracjectory on the back of the strong infra spends. Overall, we expect all the segments of the company to register high growth and conservatively expect total revenues to register 21.5% CAGR over CY2010-12.

(₹ cr) (%) 1,000 45 900 40 800 35 700 30 600 352 25 500 286 20 238 400 226 62 15 168 300 60 100 10 200 107 100 130 CY07 CY08 CY09 CY10E CY11E CY12E Advisory Research Total Revenue Growth Rating

Exhibit 1: Segmental revenue breakup

Source: Company, Angel Research

Strong growth to continue on the back of acquisition Pipal

CRISIL has a history of acquiring small companies and scaling their operations by leveraging their strong clientele, skills and processes. CRISIL acquired Irevna in CY2005 for ₹73.1cr, which was valued at ~2.2x EV/Sales (₹33.1cr sales). Post the acquisition, CRISIL's research segment's revenue increased from ₹41cr in CY2005 to ₹238cr in CY2009, witnessing a 55.7% CAGR in revenue over CY2005–09, contributing nearly 45% to the total revenue in CY2009 from 29% in CY2005.

In CY2009, Datamonitor's The Black Book of Outsourcing for Financial Research ranked Irevna as the number one research house in the country.






Exhibit 2: Strong revenue growth post Irevna's acquisition

CRISIL recently acquired Chicago-based Pipal Research Corp., one of the leading players in the knowledge process outsourcing (KPO) industry, from First Source Solution for US \$12.75mn (around ₹58cr), at 1.6x EV/Sales . Pipal has a strong presence in the corporate sector mainly in North America and Europe and reported revenue of US \$8.1mn (around ₹37cr) in FY2010. Pipal's client base includes leading telecommunications, technology, consumer packaged goods and industrial companies.

Currently, CRISIL is a leader in the high-end KPO space. With this acquisition, CRISIL, which provides services from Chennai, Mumbai, Buenos Aires and Wroclaw (Poland), will now have presence in Gurgaon, Noida, Bangalore and Chicago. The acquisition will also strengthen its position in the market. Pipal has strong presence in the corporate sector, while Irevna's strong presence lies in the financial sector. The synergy between the two firms will help the company to service clients better and expand its client base, which will result in a strong platform for growth in the coming years.

Going ahead, we expect CRISIL's research segment to grow further, as it did post the acquisition of Irevna, registering a 22% CAGR over CY2010–12E.




Exhibit 3: Robust growth to continue post Pipal's acquisition

Robust growth in credit ratings to continue on strong credit demand

The Indian economy is on the cusp of an upturn in its capex cycle, and early signs of a pronounced capex upswing are already emerging. GDP growth has averaged at about 8% over the last five years and is expected to grow at 8–9% over the next few years.

We believe macro indicators such as huge project announcements, improving utilisation levels, improved business confidence, increasing end-product prices and expectation of significant demand improvement will lead to growth in the capex cycle. Funds raised by companies grew by 20.5% in FY2010 compared to 18% in FY2009. The capex cycle, which started in 2004, took a breather between 2008 and 2009 as the world faced liquidity constraints.

After the interruption seen over the last two years, the capex cycle has resumed and is expected to further improve going ahead. Rising economic growth momentum, improving domestic demand prospects and growing capacity utilisation since FY2009 have translated into recent growth in capacity expansion plans as well as in actual project implementation. Moreover, the continuous flow of investment announcements reflects the confidence of industries in sustaining the current upsurge in demand. More importantly, the current investment boom is not triggered by the government but by companies that are optimistic about the economy's growth potential and are investing willingly. This is evident from the fact that the share of private sector in outstanding investment has been rising steadily from 39% in 2004 to 58% in 2010.

We believe credit demand will continue to grow at a faster rate than India's nominal GDP as financial depth continues to increase. The need for large capital formation of 30–35% of GDP for sustaining 8%+ GDP growth in India is well acknowledged; hence, we expect credit demand to witness a 20% CAGR over CY2010–14, considering the actual and latent credit demand in India.

CRISIL has been growing at \sim 2x India's credit growth since CY2005. Further, the company will continue to benefit from Basel II norms, as the number of entities to be rated will increase further. CRISIL, being the market leader with 65% market



share in credit rating, will continue to benefit greatly from India's strong credit growth. As of September 30, 2010, CRISIL had more than 10,941 ratings (including 6030 SMEs) outstanding. We conservatively expect the rating business to register 21% revenue CAGR over CY2010–12.

(%) 60 51 45 50 44 40 40 27 30 19 30 30 20 24 22 10 14 13.3 CY05 CY06 CY07 CY08 CY09 9MCY10 Crisil Ratings Growth → Indian Credit Growth

Exhibit 4: Credit rating business growing on the back of credit growth

Source: Company, Angel Research

Robust growth in BLR to continue post Basel II

Post Basel II, CRISIL has seen strong growth in its credit rating segment due to a boost in bank loan rating (BLR). The company's credit rating segment witnessed a 38.2% CAGR in revenue over CY2006–09. Till 3QCY2010, CRISIL had 5,017 BLRs, making it the market leader with a market share of 50%.

The BLR market is a much larger market compared to the bond market given the wide reach of banks and large funds at their disposal vis-à-vis the capital market participants. There are several incentives for entities to get rated, as they can avail loans at cheaper rates based on their ratings. On the other hand, banks also stand to benefit, as they now only need to hold capital reserves to the extent of the risks they are exposed to, in turn freeing vital capital and reducing costs. Thus, given the large size of the SME sector and high number of unrated entities under Base II norms, we believe that the BLR market presents a strong growth opportunity.



Exhibit 5: Potential savings in interest rates on getting rated

Rating	Bas	el I			Basel II				
	Risk weight (%)	Capital required (₹ cr)	Risk weight (%)	Capital required (₹ cr)	PBT required by bank	PBT required by bank due to lower risk weight (% to assets)	Potential reduction in interest rates		
AAA	100	9	20	1.8	1.4	0.3	1.1		
AA	100	9	30	2.7	1.4	0.4	1.0		
A	100	9	50	4.5	1.4	0.7	0.7		
BBB	100	9	100	9.0	1.4	1.4	-		
BB and below/ or unrated exposure	100	9	150	13.5	1.4	2.1	(0.7)		

Source: RBI, Note1: Calculations made assuming a bank would like to make a profit of ₹1cr on a ₹100cr loan i.e. 1% RoA. Note 2: Unrated exposure above ₹10cr will attract 150% risk weight on full transition to Basel II, irrespective of an entity's actual creditworthiness.


Post 2014, the RBI may shift to the advanced internal ratings methodology under Basel II norms, where banks can themselves rate entities. However, it is better for an entity to get rated from a single, well-accepted external agency than getting rated by multiple banks and increase its cost of rating. Hence, CRISIL being the market leader will benefit the most from the growing BLR market.

India's bond issuance growth to fuel further growth in ratings

Bond rating is one of the major contributors to the company's ratings segment. India's corporate bond market is relatively underpenetrated compared to major developed countries and emerging markets, as corporates in India prefer bank credit over bonds. However, with the growing capex cycle and infra spends in the recent years, corporate bond issuance has increased, as it is a cheaper way to raise money compared to bank loans or equity dilution.


For India to expand at 8–9% in the coming decade, huge capex and infra spends are required. As per the XIIth Five-Year Plan, the government has announced US \$1tn infrastructure spending. Accordingly, we expect bonds to become a major source for corporates to raise money to fuel such a huge amount of spending.

Exhibit 6: Indian corporate bond market showing robust growth



Source: Bloomberg, Angel Research

Exhibit 7: Largely underpenetrated corporate bond market



Source: IMF, Bloomberg, Angel Research



Infra & advisory services to benefit from huge infra spend

CRISIL's infrastructure advisory segment provides practical and innovative solutions to governments, donor-funded agencies and leading organisations, where the company helps to improve infrastructure service delivery, transform performance of public institutions and design and strengthen reform programs to catalyse private sector participation.

Over CY2007–09, CRISIL's infra and risk advisory segment took a hit due to the ongoing liquidity crisis. Consequently, the segment's revenue declined from ₹107cr in CY2007 to ₹60cr in CY2009. However, post the crisis, we expect the segment to recover at a fast pace and register revenue close to its CY2007 revenue.

CRISIL is set to benefit from the estimated US \$800bn spend on infrastructure from FY2010–14E (US \$1tn in the XIIth Five-Year Plan), as it will provide a huge opportunity to the company to expand its infra and risk advisory services segment. Accordingly, CRISIL has undertaken aggressive hiring across hierarchy and will expand its customer base going ahead.

7,415 Industrial 14,642 ਹੈ O Infrastructure 9,008 28,349 16,423 **Total Investments** 42,991 0 10,000 20,000 30,000 40,000 50,000 ■ FY2006-10 ■ FY2011-15E

Exhibit 8: Estimated infra and industrial spending

Source: CRISIL Research, Angel Research

Hence, we expect CRISIL's infra and risk advisory services segment to conservatively report a 21.7% CAGR over CY2010–12E on account of low revenue base. Despite such strong growth, the advisory segment is expected to report revenue of ₹75cr in CY2012, which will be less than its CY2007 revenue of ₹107cr. Thus, there could be significant upside to our estimates.



(₹ cr) 120 30.0 107 100 20.0 100 10.0 75 80 62 60 (10.0)60 51 (20.0)40 (30.0)20 (40.0)0 (50.0)CY08 CY07 CY10E CY09 CY11E CY12E Advisory Revenue Growth (yoy)

Exhibit 9: Advisory division to recover due to strong infra spends

Strong cash reserves to result in buyback, acquisitions and higher dividends

CRISIL, with its strong cash reserves of ₹158cr, initiated a buyback of ~1.3lakh shares worth ₹80cr for an average price of ₹6,200/share in CY2010. The company also purchased Pipal for ₹58cr. In CY2010, apart from the ₹75/share dividend, CRISIL gave a special dividend of ₹100/share.

Going ahead, we expect this trend to continue with the company paying higher dividend with payout ratio above 50% in CY2011–12. Also, the company can initiate another round of buyback in CY2011, as it will have ₹142cr of cash reserve post an estimated dividend payout of ₹150/share in CY2011. CRISIL has historically taken up many inorganic growth opportunities to fuel its growth and can easily accept another inorganic growth prospect, given its strong cash reserve of ₹242cr by CY2012E.



Outlook and valuation

We expect CRISIL to register a 21.5% CAGR in revenue over CY2010–12E and continue to maintain its leadership position, with robust growth across all its segments. The company benefits from its asset-light business model, which is high on intellectual assets (employee cost-to-sales is around 40%). Further, the company is debt free and has 40% plus RoE. Additionally, the company enjoys strong parentage (Standard and Poor's).


Currently, the stock is available 17.3x CY2012E earnings, which is at the lower end of its historical range of 16.4–29.9x one-year forward EPS, which makes it attractive. We Initiate Coverage on the stock with a Buy rating and a Target Price of ₹7,584, valuing it at its five-year median of 22x CY2012E earnings and implying an upside of 27%.

Exhibit 10: Peer comparison

	Target Price	Mkt. Cap.	Sa	les	Sales Growth (%)	OPA	۸ (%)	EPS	(₹)	EPS Growth (%)	PER	(x)	RoE	: (%)
(₹ cr)	(₹)		CY11E	CY12E	CY12E (yoy)	CY11E	CY12E	CY11E	CY12E	CY12E (yoy)	CY11E	CY12E	CY11E	CY12E
CRISIL Angel	7,584	4,245	767	927	20.0	34.3	34.8	282.0	344.7	22.3	21.2	17.3	44.9	46.8
CRISIL Blmberg	N/A	4,245	785	958	22.0	36.5	37.7	282.8	372.9	31.9	21.1	16.0	50.5	53.9
ICRA* Blmberg	N/A	1,165	247	295	19.4	39.0	39.0	72.7	89.2	22.7	16.0	13.1	26.2	26.3

Source: Company, Angel Research, Bloomberg, *FY2012-13E

Exhibit 11: One-year forward P/E band



Source: Company, Angel Research



Concerns

Slowdown in economic growth

CRISIL's rating business depends on growth in credit demand, which is closely linked to the economy's growth. A major part of research revenue is generated through outsourcing research services to foreign corporate and institution, which may be affected if economic crisis continues in the near future.

Competition from other players

CRISIL enjoys the highest market share in industry. However, growing competition from players such as ICRA, CARE, Fitch Rating and Brickwork has seen erosion in its market share as seen in the case of BLR where CRISIL's market share has dipped to 50% in 3QCY2010 from 55% in CY2009. Going forward, this could result in declining growth and have negative impact on the company's profitability. Nonetheless, CRISIL being the market leader since inception is well-placed to fend off such competition, which we believe is there to stay.

Exhibit 12: Market share still highest amidst intensifying competition

Quarter	Ratings Announced	Market Share (%)
CY2007	15	42
CY2008	842	46
CY2009	2,268	55
3QCY2010	5,017	50

Source: Company, Angel Research

Margins at risk due to fluctuations in forex

CRISIL derives \sim 53% of its revenue from foreign clients. Thus, the company has a large exposure to foreign currency and any major fluctuation in forex can lead to losses, thus affecting margins and profitability.

Wage inflation and attrition rate cause of concern

CRISIL has been facing attrition in excess of 15% over the years. In the face of it, the company has been incurring significant costs towards acquiring and training qualified manpower. Also, in its efforts to retain talent, CRISIL has seen an increase in cost per employee due to inflationary effects. However, it may be noted that it has been able to increase its profit and revenue per employee over the years exhibiting strong capability to pass on additional expenses. Overall, we believe that being a market leader with a strong brand, the company will be able to manage such pressures and sustain its margins going ahead.



(₹ lakh) 30 26.3 24.8 23.1 25 19.4 20 15 9.8 9.6 8.7 7.7 10 7.2 4.8 4.1 5 CY2007 CY2006 CY2008 CY2009 ■ Revenue/Employee ■ Staff expense/Employee ■ Profit/Employee

Exhibit 13: Revenue per employee rising despite wage inflation



Financial overview

In CY2009, CRISIL registered mediocre growth of 4.4% yoy in revenue, largely due to the slowdown in capital expenditure during the economic downturn. However, on the back of a revival in the economy, the company registered robust 16% yoy growth in revenue for 9MCY2009 to ₹453.7cr from ₹391.7cr, aided by strong growth in the credit rating and research segments.

For 4QCY2010E, we expect strong growth across all segments as the economy is back on track, with an estimated GDP growth of around 8.5%. For CY2010, we expect strong top-line growth of ₹91cr (17%) yoy to ₹629cr compared to ₹537cr in CY2009, largely due to strong growth in the credit rating and research segments, which are expected to post 22% and 20% yoy growth, respectively. Further, we expect all segments to register strong growth on the back of robust credit demand, acquisition of Pipal and strong infrastructure spend in the coming years.

Going ahead, we expect the company's top line to register a 21.5% CAGR over CY2010–12E, increasing to ₹767cr in CY2011 and ₹927cr in CY2012.

(₹ cr) (%) 1,000 45 900 40 800 35 427 700 30 600 352 25 500 286 20 238 400 226 62 168 15 51 300 60 100 10 200 107 5 100 130 CY07 CY08 CY09 CY10E CY11F CY12F Rating Advisory Research Total Revenue Growth

Exhibit 14: Strong turnaround in growth due to economic recovery

Source: Company, Angel Research

EBITDA margins to remain in line

During CY2009, CRISIL's operating margin improved to 37.1% (34.8%), largely on the back of cost cutting, which resulted in other expenses coming down to 14% of revenue in CY2009 versus 18% in CY2008. However, for 9MCY2010, the operating margin reduced marginally by 4.3% to 32.8% yoy due to higher employee cost and other expenses, which included forex losses of ₹7.3cr for 9MCY2010.

CRISIL's margins, which took a hit in the first two quarters of CY2010, improved to 35.3% in 3QCY2010 due to lower other expenses. For 4QCY2010E, we believe the company's EBITDA margin will be at around 34.4%. For CY2010E, we estimate EBITDA margin of 33.3%, which is expected to come back to its CY2008 levels going ahead and gradually increase to 34.3% and 34.8% in CY2011E and CY2012E, respectively. EBITDA is estimated to increase from ₹199cr in CY2009 to ₹323cr in FY2012E on the back of strong revenue growth.






Exhibit 15: EBITDA margins expected to remain stable

Net profit to register 15% CAGR over CY2009-12E

In CY2009 CRISIL's net profit margin increased by 261bp to 29.9% (27.3%), primarily because of higher operating margins. For CY2010, we estimate net profit margin to increase substantially to 32.1% (29.9%) on the back of higher other income arising from sale of property and investments. For 9MCY2010, net profit surged 32.6% yoy to ₹155cr from ₹117cr due to the 306% yoy spike in other income. Thus, in CY2010 net profit is expected to increase to ₹202cr from ₹161cr in CY2009.

CRISIL derives a major part of its revenue from exports, which is tax-exempted till FY2011 under the Software Technology Parks of India's (STPI) regulations. Going ahead, this exemption will seize and, thus, the company has started taking necessary steps such as transferring business to its existing SEZ units, where the company can continue to avail tax exemption. Management has guided that tax exemption may be extended till FY2012 under the STPI. If tax exemptions under the STPI are not extended till FY2012, we expect the company's tax rate to increase by ~2% in CY2012. For CY2011 and CY2012, we estimate net profit margin to decline to 26.1% and 26.4% to ₹200cr and ₹245cr, respectively, due to lower other income in CY2011 and CY2012 and higher tax rate in CY2012.



(₹ cr) 300 (%) 35.0 32.1 29.9 27.3 30.0 26.4 250 26.1 25.0 200 20.0 150 15.0 100 10.0 50 5.0 245 141 161 202 200 CY08 CY09 CY10E CY11E CY12E ■ PAT —— Margin

Exhibit 16: PAT margins to come back to historical levels



Company background

CRISIL was incorporated in 1987 as India's first credit rating agency. Over the years, the company has evolved to become the industry leader with a market share of around 65% and has diversified into research and infrastructure risk and policy advisory services. The company is currently one of the largest research houses in the country, providing research to over 65 industries and 150 corporates in India. The company also provides high-end offshore research and analytical services mainly to top financial institutions (including six of the world's top 10 investment banks), insurance companies and asset management firms.

Credit rating segment

CRISIL is the largest credit rating agency in India. CRISIL pioneered ratings in India more than 20 years ago and is today the undisputed business leader, with the largest number of rated entities and products. Over the years, CRISIL has also developed several structured ratings for multinational entities based on guarantees from the parent as well as standby letter of credit arrangements from bankers. The rating agency has also developed a methodology for credit enhancement of corporate borrowing programmes through the use of partial guarantees. CRISIL is uniquely placed in its experience in understanding the extent of credit enhancement arising out of such structures. CRISIL's comprehensive offerings include ratings for long-term instruments such as debentures/bonds and preference shares, structured obligations (including asset-backed securities) and fixed deposits. The company also rates short-term instruments such as commercial paper programmes and short-term deposits.

Bank Loan Ratings (Basel II)

CRISIL commenced rating bank loans post the RBI's guidelines on capital adequacy for banks in 2007. Basel II guidelines, as they are called, require banks to provide capital on credit exposure as per credit ratings assigned by approved external credit assessment institutions (ECAIs), such as CRISIL. Basel II is a recommendatory framework for banking supervision issued by the Basel Committee on Banking Supervision in June 2004. The objective of Basel II is to bring about international convergence of capital measurement and standards in the banking system. The revised framework for capital adequacy has been effective from March 31, 2008, for all Indian banks with an operational presence outside India (12 public sector banks and five private sector banks) and for all foreign banks operating in India. It has been applicable to all other commercial banks (except local area banks and regional rural banks) from March 31, 2009.

CRISIL rates the maximum number of companies for their bank loans in India. As of September 30, 2010, CRISIL had rated 5,017 entities, representing over 50% of all the companies, which have their bank loans rated in India; CRISIL has rated bank facilities of all types: term loans, project loans, corporate loans, general purpose loans, working capital demand loans, cash credit facilities and non-fund-based facilities, such as letters of credit and bank guarantees.



	4	C D I I	D 1	
Exhibit	17: Distribution of	at Kank Loan	Ratinas hy	Inan size
	17. 0131110011011	JI DAIIK LOAII	IVALLINGS BY	IOGII JILC

Loan Size	No. of ratings upto	% of total	No. of ratings upto	% of total
(₹ cr)	1QCY2009	2008	1QCY2010	2009
<10	70	5	503	13
10-25	270	19	1,232	32
25-50	234	17	764	20
50-250	553	40	977	26
250-500	112	8	161	4
>500	161	12	188	5
Total	1,400	100	3,825	100

Source: Company, Angel Research, Data available only till 1QCY2010, 5017 entities rated till 3QCY2010.

SME Ratings

CRISIL pioneered the concept of ratings for the SME sector in India and, presently, within a span of just five years, has the largest number of ratings on the SME sector in the world. As of September 30, 2010, CRISIL had assigned ratings to over 14,500 SMEs. CRISIL's SME ratings are affordable and tailor-made services designed for SMEs.

Real Estate Ratings

Housing and real estate form the backbone of the country's infrastructure and are critical drivers of economic development. With government policies emphasising faster economic growth, the real estate sector is attracting large investments from both domestic and foreign investors. Investors and customers, however, need to exercise caution in their exposure, as the sector is largely unorganised.

Given the risk factors and volatility inherent in the real estate business, it is critical to judge the performance ability of developers to deliver good quality projects. Towards this end, CRISIL provides third-party opinion through two specialised products: National Developer Ratings and Real Estate Star Ratings.

Research

CRISIL Research: CRISIL's research segment is India's leading independent, integrated research house. Through constant innovation and comprehensive research offerings covering the economy, industry and companies, CRISIL Research meets the requirements of more than 750 Indian and global clients. Apart from off-the-shelf research reports, CRISIL provides incisive, customised research. Through its IPO grading initiative, CRISIL Research has also established a presence in the equity research domain and is poised to significantly expand its presence in this area.

Outsourcing (Irevna and Pipal): CRISIL's outsourcing department consists of Irevna and the recently acquired Pipal. Irevna was one of the pioneers of offshore investment research for some of the world's leading investment banks and financial institutions. It is one of the most experienced and diversified provider of analytical services to the financial services industry, supporting equity research, equity strategy, credit research, securitisation research, and derivatives IT and



structuring. Irevna has offices across the world in the US, the UK, Poland, Argentina and Hong Kong and its Indian offices are at Mumbai and Chennai.

Pipal is a leading custom research firm, delivering financial and business research and quantitative analytics to organisations worldwide. Founded in 2001 by a team of management professionals, Pipal created a name for itself as a knowledge vendor of choice.



Advisory

CRISIL Infrastructure Advisory: CRISIL's infrastructure advisory segment provides practical and innovative solutions to governments, donor-funded agencies and leading organisations in over 20 emerging economies across the world. It has widely acknowledged policy advisory expertise and specialises in commercial and contractual issues in the areas of energy, urban infrastructure and public-private partnerships. CRISIL Infrastructure Advisory has built a unique position for itself in these domains and is the preferred consultant to governments, multilateral lending agencies and private sector clients.

CRISIL Risk: This segment provides risk solutions for banks, financial institutions, mutual funds and corporates. It also provides risk management services, consulting and software products in the areas of credit, market and operational risk. It partners closely with leading public and private sector banks and entities in the financial services and insurance sectors, implementing enterprise-wide risk management solutions.



Profit & Loss Statement (Consolidated)

Y/E Dec.	CY2008	CY2009	CY2010E	CY2011E	CY2012E
Net Sales	515	537	629	767	927
% chg	27.3	4.4	17.0	22.0	20.0
Total Expenditure	335	338	419	504	605
Establishment Expenses	52	55	64	78	92
Other Expenses	93	75	94	115	138
Personnel	191	208	261	311	375
EBITDA	179	199	209	263	323
% chg	52.8	11.3	5.0	25.7	22.7
(% of Net Sales)	34.8	37.1	33.3	34.3	34.8
Depreciation& Amortisation	14	15	21	24	26
EBIT	165	184	188	239	297
% chg	63.0	11.5	1.9	27.0	24.4
(% of Net Sales)	32.1	34.3	29.9	31.1	32.0
Interest & other Charges	-	-	-	-	-
Other Income	22	23	72	20	27
(% of PBT)	11.6	11.1	27.8	7.6	8.3
Recurring PBT	187	207	260	258	324
% chg	69.1	10.9	25.4	(0.8)	25.5
PBT (reported)	187	207	260	258	324
Tax	46	47	59	58	79
(% of PBT)	24.8	22.5	22.5	22.5	24.5
PAT (reported)	141	161	202	200	245
% chg	68.0	14.4	25.4	(0.8)	22.3
Prior period items	-	-	-	-	-
PAT after MI (reported)	141	161	202	200	245
Extraordinary Income (post tax)	-	-	45	-	-
ADJ. PAT	141	161	157	200	245
% chg	68.0	14.4	(2.5)	27.7	22.3
(% of Net Sales)	27.3	29.9	24.9	26.1	26.4
Basic EPS (Rs)	194.6	222.5	284.2	282.0	344.7
Fully Diluted EPS (Rs)	194.6	222.5	284.2	282.0	344.7
% chg	68.0	14.4	27.7	(0.8)	22.3



Balance Sheet (Consolidated)

Y/E Dec.	CY2008	CY2009	CY2010E	CY2011E	CY2012E
SOURCES OF FUNDS					
Equity Share Capital	7.2	7.2	7.1	7.1	7.1
Reserves& Surplus	350	427	401	476	555
Shareholders Funds	358	434	408	483	562
Total Loans	-	-	-	-	-
Deferred Tax Liability	-	-	-	-	-
Total Liabilities	358	434	408	483	562
APPLICATION OF FUNDS					
Gross Block	190	192	300	324	330
Less: Acc. Depreciation	64	72	93	118	143
Net Block	126	120	207	206	187
Capital Work-in-Progress	4	64	14	-	-
Investments	118	118	118	118	118
Current Assets	261	323	255	370	507
Cash	129	158	64	142	242
Loans & Advances	53	62	68	75	82
Other Current Assets	2	11	12	12	13
Debtors	77	92	112	141	170
Other	-	-	-	-	-
Current liabilities	160	200	195	221	260
Net Current Assets	101	122	60	150	247
DEFERRED TAX ASSETS (Net)	8	10	10	10	10
Total Assets	358	434	408	483	562



Cash Flow (Consolidated)

Y/E Dec.	CY2008	CY2009	CY2010E	CY2011E	CY2012E
Profit before tax	187	207	260	258	324
Depreciation	14	15	21	24	26
Change in Working Capital	36	16	(25)	(4)	9
Less: Other income	22	23	72	20	27
Direct taxes paid	46	47	59	58	79
Cash Flow from Operations	169	169	126	201	253
Inc./ (Dec.) in Fixed Assets	0	(62)	(58)	(10)	(6)
Inc./ (Dec.) in Investments	(21)	1	-	-	-
Inc./ (Dec.) in loans and advances	(12)	(9)	(6)	(7)	(7)
Other income	22	23	72	20	27
Cash Flow from Investing	(11)	(47)	8	3	13
Issue/(Buy Back) of Equity	-	-	(79)	-	-
Inc./(Dec.) in loans	-	-	-	-	-
Dividend Paid (Incl. Tax)	(59)	(85)	(148)	(125)	(166)
Others	(12)	(9)	-	-	-
Cash Flow from Financing	(71)	(93)	(227)	(125)	(166)
Inc./(Dec.) in Cash	87	28	(94)	79	100
Opening Cash balances	42	129	158	64	142
Closing Cash balances	129	158	64	142	242



Key Ratios

Y/E Dec.	CY2008	CY2009	CY2010E	CY2011E	CY2012E
Valuation Ratio (x)					
P/E (on FDEPS)	30.7	26.9	21.0	21.2	17.3
P/BV	12.1	10.0	10.4	8.8	7.6
Dividend yield (%)	1.2	1.7	2.9	2.5	3.3
Market cap. / Sales	8.2	7.9	6.7	5.5	4.6
EV/Sales	8.0	7.6	6.6	5.3	4.3
EV/EBITDA	23.0	20.5	20.0	15.6	12.4
EV / Total Assets	11.5	9.4	10.2	8.5	7.1
Per Share Data (Rs)					
EPS (Basic)	194.6	222.5	284.2	282.0	344.7
EPS (fully diluted)	194.6	222.5	284.2	282.0	344.7
Cash EPS	213.4	243.1	314.3	316.3	380.9
DPS	70.0	100.0	175.0	150.0	200.0
Book Value	494.8	600.4	574.9	681.3	791.8
Dupont Analysis (%)					
EBIT margin	32.1	34.3	29.9	31.1	32.0
Tax retention ratio	75.2	77.5	77.5	77.5	75.5
Asset turnover (x)	4.2	4.0	3.3	3.4	4.4
ROIC (Post-tax)	100.9	106.4	75.5	82.1	105.2
Operating ROE	100.9	106.4	75.5	82.1	105.2
Returns (%)					
ROCE (Pre-tax)	52.2	46.6	44.6	53.6	56.8
Angel ROIC (Pre-tax)	141.2	183.6	122.0	109.4	139.4
ROE	44.3	40.6	47.9	44.9	46.8
Turnover ratios (x)					
Asset Turnover (Gross Block)	2.7	2.8	2.6	2.5	2.8
Asset Turnover (Net Block)	4.0	4.4	3.8	3.7	4.7
Asset Turnover (Total Assets)	1.6	1.4	1.5	1.7	1.8
Operating Income / Invested Capital	4.2	4.0	3.3	3.4	4.4
Receivables (days)	59	58	59	60	61
Payables (days)	104	122	115	99	95
Working capital cycle (ex-cash) (days)	(11)	(21)	(11)	1	2



DISCLAIMER

This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment.

Angel Broking Limited, its affiliates, directors, its proprietary trading and investment businesses may, from time to time, make investment decisions that are inconsistent with or contradictory to the recommendations expressed herein. The views contained in this document are those of the analyst, and the company may or may not subscribe to all the views expressed within.

Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals.

The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Angel Broking Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Angel Broking Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Limited endeavours to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly.

Angel Broking Limited and its affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past.

Neither Angel Broking Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information.

Note: Please refer to the important `Stock Holding Disclosure' report on the Angel website (Research Section). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. Angel Broking Limited and

Disclosure of Interest Statement	Crisil
1. Analyst ownership of the stock	No
2. Angel and its Group companies ownership of the stock	No
3. Angel and its Group companies' Directors ownership of the stock	No
4. Broking relationship with company covered	No

Note: We have not considered any Exposure below ₹1 lakh for Angel, its Group companies and Directors.

Ratings (Returns) :	Buy (> 15%)	Accumulate (5% to 15%)	Neutral (-5 to 5%)
	Reduce (-5% to 15%)	Sell (< -15%)	



6th Floor, Ackruti Star, Central Road, MIDC, Andheri (E), Mumbai- 400 093. Tel: (022) 39357800

Research Team

Simran Kaur

Bharat Patil

Dilip Patel

Research Team		
Fundamental:		
Sarabjit Kour Nangra	VP-Research, Pharmaceutical	sarabjit@angelbroking.com
Vaibhav Agrawal	VP-Research, Banking	vaibhav.agrawal@angelbroking.com
Vaishali Jajoo	Automobile	vaishali.jajoo@angelbroking.com
Shailesh Kanani	Infrastructure	shailesh.kanani@angelbroking.com
Rupesh Sankhe	Cement, Power	rupeshd.sankhe@angelbroking.com
Param Desai	Real Estate, Logistics, Shipping	paramv.desai@angelbroking.com
Sageraj Bariya	Fertiliser, Mid-cap	sageraj.bariya@angelbroking.com
Paresh Jain	Metals & Mining	pareshn.jain@angelbroking.com
John Perinchery	Capital Goods	john.perinchery@angelbroking.com
Srishti Anand	IT, Telecom	srishti.anand@angelbroking.com
Jai Sharda	Mid-cap	jai.sharda@angelbroking.com
Sharan Lillaney	Mid-cap	sharanb.lillaney@angelbroking.com
Naitik Mody	Mid-cap	naitiky.mody@angelbroking.com
Chitrangda Kapur	FMCG, Media	chitrangdar.kapur@angelbroking.com
Amit Vora	Research Associate (Oil & Gas)	amit.vora@angelbroking.com
V Srinivasan	Research Associate (Cement, Power)	v.srinivasan@angelbroking.com
Mihir Salot	Research Associate (Logistics, Shipping)	mihirr.salot@angelbroking.com
Pooja Jain	Research Associate (Metals & Mining)	pooja.j@angelbroking.com
Yaresh Kothari	Research Associate (Automobile)	yareshb.kothari@angelbroking.com
Shrinivas Bhutda	Research Associate (Banking)	shrinivas.bhutda@angelbroking.com
Sreekanth P.V.S	Research Associate (FMCG, Media)	sreekanth.s@angelbroking.com
Hemang Thaker	Research Associate (Capital Goods)	hemang.thaker@angelbroking.com
Nitin Arora	Research Associate (Infra, Real Estate)	nitin.arora@angelbroking.com
Ankita Somani	Research Associate (IT, Telecom)	ankita.somani@angelbroking.com
Varun Varma	Research Associate (Banking)	varun.varma@angelbroking.com
Vasant Lohiya	Research Associate (Banking)	vasant.lohiya@angelbroking.com
Technicals:	, ,	
Shardul Kulkarni	Sr. Technical Analyst	shardul.kulkarni@angelbroking.com
Mileen Vasudeo	Technical Analyst	vasudeo.kamalakant@angelbroking.com
Derivatives:	,	
Siddarth Bhamre	Head - Derivatives	siddarth.bhamre@angelbroking.com
Jaya Agarwal	Derivative Analyst	jaya.agarwal@angelbroking.com
Institutional Sales Team:		
Mayuresh Joshi	VP - Institutional Sales	mayuresh.joshi@angelbroking.com
Abhimanyu Sofat	AVP - Institutional Sales	abhimanyu.sofat@angelbroking.com
Pranav Modi	Sr. Manager	pranavs.modi@angelbroking.com
Ganesh Iyer	Sr. Manager	ganeshb.lyer@angelbroking.com
Jay Harsora	Manager	jayr.harsora@angelbroking.com
Meenakshi Chavan	Dealer	meenakshis.chavan@angelbroking.com
Gaurang Tisani	Dealer	gaurangp.tisani@angelbroking.com
Production Team:		
Bharathi Shetty	Research Editor	bharathi.shetty@angelbroking.com
0: 1/	B 1 - 10	

Angel Broking Ltd: BSE Sebi Regn No: INB 010996539 / CDSL Regn No: IN - DP - CDSL - 234 - 2004 / PMS Regn Code: PM/INP000001546 Angel Securities Ltd: BSE: INB010994639/INF010994639 NSE: INB230994635/INF230994635 Membership numbers: BSE 028/NSE:09946
Angel Capital & Debt Market Ltd: INB 231279838 / NSE FNO: INF 231279838 / NSE Member code - 12798 Angel Commodifies Broking (P) Ltd: MCX Member ID: 12685 / FMC Regn No: MCX / TCM / CORP / 0037 NCDEX : Member ID 00220 / FMC Regn No: NCDEX / TCM / CORP / 0302

simran.kaur@angelbroking.com

bharat.patil@angelbroking.com

dilipm.patel@angelbroking.com

Research Editor

Production

Production